Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: Results from a large pooled analysis

G. Procopio; J. Bellmunt; J. Dutcher; S. Bracarda; J. Knox; A. Brueckner; I. Molnar; B. Escudier; T. E. Hutson

doi:10.1038/bjc.2012.543

Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: Results from a large pooled analysis

G. Procopio, J. Bellmunt, J. Dutcher, S. Bracarda, J. Knox, A. Brueckner, I. Molnar, B. Escudier, T. E. Hutson

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journal › Article › peer-review

Abstract

Background:Elderly patients tend to be underrepresented in renal cell carcinoma (RCC) clinical trials. The Sorafenib RCC Integrated Database includes data from six clinical trials and two expanded-access studies evaluating sorafenib monotherapy in >4600 patients with RCC. Using this database, sorafenib tolerability and treatment patterns were analysed according to age group (

Original language	English
Pages (from-to)	311-318
Number of pages	8
Journal	British Journal of Cancer
Volume	108
Issue number	2
DOIs	https://doi.org/10.1038/bjc.2012.543
Publication status	Published - Feb 2013

Keywords

Elderly
Renal cell carcinoma
Sorafenib
Targeted therapies
Tyrosine kinase inhibitors

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1038/bjc.2012.543

Fingerprint Dive into the research topics of 'Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: Results from a large pooled analysis'. Together they form a unique fingerprint.

Cite this

Sorafenib tolerability in elderly patients with advanced renal cell carcinoma : Results from a large pooled analysis. / Procopio, G.; Bellmunt, J.; Dutcher, J.; Bracarda, S.; Knox, J.; Brueckner, A.; Molnar, I.; Escudier, B.; Hutson, T. E.

In: British Journal of Cancer, Vol. 108, No. 2, 02.2013, p. 311-318.

Research output: Contribution to journal › Article › peer-review

@article{502c8babf3e54a5b83db2e32a93bffeb,

title = "Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: Results from a large pooled analysis",

abstract = "Background:Elderly patients tend to be underrepresented in renal cell carcinoma (RCC) clinical trials. The Sorafenib RCC Integrated Database includes data from six clinical trials and two expanded-access studies evaluating sorafenib monotherapy in >4600 patients with RCC. Using this database, sorafenib tolerability and treatment patterns were analysed according to age group (",

keywords = "Elderly, Renal cell carcinoma, Sorafenib, Targeted therapies, Tyrosine kinase inhibitors",

author = "G. Procopio and J. Bellmunt and J. Dutcher and S. Bracarda and J. Knox and A. Brueckner and I. Molnar and B. Escudier and Hutson, {T. E.}",

year = "2013",

month = feb,

doi = "10.1038/bjc.2012.543",

language = "English",

volume = "108",

pages = "311--318",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Sorafenib tolerability in elderly patients with advanced renal cell carcinoma

T2 - Results from a large pooled analysis

AU - Procopio, G.

AU - Bellmunt, J.

AU - Dutcher, J.

AU - Bracarda, S.

AU - Knox, J.

AU - Brueckner, A.

AU - Molnar, I.

AU - Escudier, B.

AU - Hutson, T. E.

PY - 2013/2

Y1 - 2013/2

N2 - Background:Elderly patients tend to be underrepresented in renal cell carcinoma (RCC) clinical trials. The Sorafenib RCC Integrated Database includes data from six clinical trials and two expanded-access studies evaluating sorafenib monotherapy in >4600 patients with RCC. Using this database, sorafenib tolerability and treatment patterns were analysed according to age group (

AB - Background:Elderly patients tend to be underrepresented in renal cell carcinoma (RCC) clinical trials. The Sorafenib RCC Integrated Database includes data from six clinical trials and two expanded-access studies evaluating sorafenib monotherapy in >4600 patients with RCC. Using this database, sorafenib tolerability and treatment patterns were analysed according to age group (

KW - Elderly

KW - Renal cell carcinoma

KW - Sorafenib

KW - Targeted therapies

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84873566624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873566624&partnerID=8YFLogxK

U2 - 10.1038/bjc.2012.543

DO - 10.1038/bjc.2012.543

M3 - Article

C2 - 23322192

AN - SCOPUS:84873566624

VL - 108

SP - 311

EP - 318

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -